Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate on Severe Asthma Exacerbations
NCT06052267Phase 3Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate nasal spray in asthma (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Time to First Severe Clinical Asthma Exacerbation (CAE) with High Dose (HD) Fp/ABS eMDPI up to 42 months. Started Aug 2023; status: active, not recruiting.
02
Drugs
fluticasone propionate nasal spray
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06052267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052267.